Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia
Key facts
- Who runs it
- Hospital Universitario Infanta Cristina
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 152 people enrolled
- Started
- 1 Jan 2020
- Ended
- 31 Dec 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Ferric Carboxymaltose (FCM)
- Record updated
- 2 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age over 18 years; on the SWL
- Hemoglobine <13g/dL
- Referred for major elective surgery requiring hospital admission (e.g., oncologic resections such as mastectomy, colon resection, nephrectomy, hysterectomy), typically involving general anesthesia and moderate to high morbidity risk, capable of understanding and consenting to the study
- Physically and mentally able to complete assessments
Who cannot take part
- Patients with hypersensitivity to FC, or any of its excipients. • Patients with active bleeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The prevalence of preoperative anaemia in patients undergoing major surgery is approximately 30%, and is independently associated with higher mortality, a higher rate of postoperative complications, and a greater probability of receiving a transfusion. In a prehabilitation program, the evaluation and correction of anaemia in the preoperative period is essential, as it is a risk factor for transfusions and complications. The main objectives of this study were to analyse the need for blood transfusion, post-surgical complications, hospital length of stay, ICU length of stay, hospital readmissions, and surgical wound infection in patients treated with ferric carboxymaltose (FC) before surgery. A total of 152 patients were included, of whom 96 received FC before the intervention and 56 received no treatment (control group).
The 2 groups in the trial
- Control (Not surgical prehabilitation)
This group received the standard preoperative patient assessment without going through a prehabilitation unit or undergoing any type of intervention. They did not receive this intervention because the surgical prehabilitation consultation had not yet been implemented at the hospital.
- Interventional group (Surgical prehabilitation)
This group received standardized care and assessments in a surgical prehabilitation consultation, including preoperative blood tests, correction of conditions such as anemia (including intravenous iron), and the necessary supplementation to optimize the patients.
Treatment: Ferric Carboxymaltose (FCM)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Role of Preoperative Intravenous Iron in Patients Undergoing Surgery
- Record updated
- 2 May 2025